2020
DOI: 10.1080/07391102.2020.1794973
|View full text |Cite
|
Sign up to set email alerts
|

The latitude hypothesis, vitamin D, and SARS-Co-V2

Abstract: The Latitude Hypothesis may explain seasonal variation in occurrence of flu and influenza-like illness, including SARS-CoV-2. We focus on one variable, vitamin D adequacy in the general population, and consider statistics of two sub-populations to propose a possible treatment to improve outcomes. Communicated by Ramaswamy H. Sarma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 19 publications
0
6
0
1
Order By: Relevance
“…Patients' reduced mobility due to persistent COVID-19 related symptoms such as fatigue and dyspnoea may also contribute to the described alterations. The recently observed peaks in new SARS-CoV-2 infections in regions with high sunlight exposure and consequently expected abundant endogenous VITD synthesis, like Florida and California, further questions the significance of VITD on COVID-19 susceptibility and disease course, contrasting with the so-called latitude hypothesis [30].…”
Section: Discussionmentioning
confidence: 98%
“…Patients' reduced mobility due to persistent COVID-19 related symptoms such as fatigue and dyspnoea may also contribute to the described alterations. The recently observed peaks in new SARS-CoV-2 infections in regions with high sunlight exposure and consequently expected abundant endogenous VITD synthesis, like Florida and California, further questions the significance of VITD on COVID-19 susceptibility and disease course, contrasting with the so-called latitude hypothesis [30].…”
Section: Discussionmentioning
confidence: 98%
“…For example, nafamostat mesylate, inhibits coronavirus entrance into human epithelial cells (EC 50 10 mM), as well as hypercoagulopathy [[ 50 ]]. There are also drugs that were shown to improve COVID-19 clinical symptoms, like convalescent plasma, corticosteroids, favipiravir, ribavirin, galidesivir, sofosbuvir, hydroxychloroquine (HCQ), azithromycin, doxycycline, lopinavir, heparin, tissue plasminogen activator, stilbene, ebelsen, metformin, tocilizumab, aculizumab, interferon β and γ, interleukinin 1 inhibitors, mesenchymal stem cells, nitric oxide, cannabidiol, N-acetylcysteine, calcifediol, vitamin C and D [[ 14 , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] ]]. Up to now, the most promising one is remdesivir, which is approved for emergency use by FDA [ www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness ], but the clinical trials are ongoing [[ 60 , 61 ]].…”
Section: Anti-oxidative Therapeutics In Covid-19mentioning
confidence: 99%
“…In fact, in Spain and Italy, there were high mortality rates due to COVID-19. One explanation for this would be that people in southern Europe, especially the elderly, avoid the intense sun, while skin pigmentation also reduces the natural synthesis of Vit-D [44]. In contrast, the highest average levels of Vit-D are found in northern Europe, due to the consumption of cod liver oil and Vit-D supplements.…”
Section: Vitamin D Status and The Covid-19 Comorbiditiesmentioning
confidence: 99%